Related references
Note: Only part of the references are listed.Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer
Bo Gong et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab
Jun Oyanagi et al.
LUNG CANCER (2019)
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
Zhijie Wang et al.
JAMA ONCOLOGY (2019)
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis
Steve Lu et al.
JAMA ONCOLOGY (2019)
Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small updates cell lung cancer patients treated with nivolumab
Julia Ouaknine Krief et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging
Benjamin M. Larimer et al.
CLINICAL CANCER RESEARCH (2019)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
Sarah B. Goldberg et al.
CLINICAL CANCER RESEARCH (2018)
Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer
Yusuke Okuma et al.
CLINICAL LUNG CANCER (2018)
Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors A meta-analysis
Wei Wei et al.
MEDICINE (2018)
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
M. A. Socinski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab
Adrien Costantini et al.
ONCOIMMUNOLOGY (2018)
Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer
Etienne Giroux Leprieur et al.
ONCOIMMUNOLOGY (2018)
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R. Gandara et al.
NATURE MEDICINE (2018)
Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy
Luc Cabel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer
Yuki Iijima et al.
EUROPEAN JOURNAL OF CANCER (2017)
Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer
Chao Li et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases
Hironori Uruga et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer
Yusuke Okuma et al.
LUNG CANCER (2017)
Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy
Jing Zhao et al.
MEDICINE (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Meta-analysis
Y. Ding et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2017)
Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma
Nicolas Guibert et al.
ONCOTARGET (2017)
Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples
David Casadevall et al.
CLINICAL LUNG CANCER (2017)
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients
M. F. Sanmamed et al.
ANNALS OF ONCOLOGY (2017)
Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study
L. Cabel et al.
ANNALS OF ONCOLOGY (2017)
Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response
Benjamin M. Larimer et al.
CANCER RESEARCH (2017)
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
M. Ilie et al.
ANNALS OF ONCOLOGY (2016)
Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer
A. S. Mansfield et al.
ANNALS OF ONCOLOGY (2016)
Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer
S. H. Lim et al.
EUROPEAN JOURNAL OF CANCER (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Comprehensive description of blood microbiome from healthy donors assessed by 16S targeted metagenomic sequencing
Sandrine Paisse et al.
TRANSFUSION (2016)
Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy
David J. Pinato et al.
ONCOIMMUNOLOGY (2016)
Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
Jin Sheng et al.
SCIENTIFIC REPORTS (2016)
Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas
Sehui Kim et al.
EUROPEAN JOURNAL OF CANCER (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
Jie Zhang et al.
THORACIC CANCER (2015)
Blood Microbiota Dysbiosis Is Associated with the Onset of Cardiovascular Events in a Large General Population: The DESIR Study
Jacques Amar et al.
PLOS ONE (2013)
Soluble B7-H1: Differences in production between dendritic cells and T cells
Xavier Frigola et al.
IMMUNOLOGY LETTERS (2012)
Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma
Xavier Frigola et al.
CLINICAL CANCER RESEARCH (2011)
Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment
Jacques Amar et al.
EMBO MOLECULAR MEDICINE (2011)
Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction
Pascal Crenn et al.
CLINICAL NUTRITION (2008)
Cytotoxic T lymphocyte-induced killing in the absence of granzymes A and B is unique and distinct from both apoptosis and perforin-dependent lysis
NJ Waterhouse et al.
JOURNAL OF CELL BIOLOGY (2006)
Granzyme B: pro-apoptotic, antiviral and antitumor functions
JA Trapani et al.
CURRENT OPINION IN IMMUNOLOGY (2003)
Share Paper
